@greatdebates.bsky.social
Great Debates hosts expert-led events tackling key issues in oncology. GD Solid Tumors focuses on emerging therapies for solid tumors, while GD Hematologic Malignancies highlights innovations in blood cancer care. Learn More: hmpglobalevents.com/gdu
Every debate, every decision, every treatment option in oncology begins with research.
This #WorldCancerResearchDay, we honor the ongoing work that fuels innovation and improves outcomes for patients everywhere.
#CancerResearch #Oncology #MedicalEducation #GreatDebates
Starting TODAY! Join @greatdebates.bsky.social
and Yelena Janjigian, Chief of the MSK Gastrointestinal Oncology Service, to learn about the latest treatments for #gastriccancer and #colorectalcancer.
@mskcancercenter.bsky.social #crcsm #GIcancer
See the full agenda 📖: bit.ly/48g13pf
Faculty from Sylvester Cancer Center will join us at Great Debates in Solid Tumors this September.
Drs. Lopes, Merchant, Paluvoi, and @latinamd.bsky.social bring the insight. Miami brings the view.
Sept 13–14 | gdsolidtumors.com
#GDST25 #Oncology #MedicalEducation
Interested in joining us? Visit gdhematology.com for more info.
18.07.2025 18:43 — 👍 0 🔁 0 💬 0 📌 0
You're making treatment decisions every day. But who’s helping you weigh the latest data, options, and gray areas in hematologic care?
Join a room full of engaged clinicians and expert voices who don’t just present the data—they challenge it.
#GDHEM #Oncology #Hematology #CancerCare
Is it time to move away from transplant in myeloma?
Dr. Rafael Fonseca and Dr. Andrew Cowan will debate the role of ASCT in today’s evolving treatment landscape.
www.gdhematology.com
#GDHEM
Dr. Ami Neghandi shares why Great Debates in Solid Tumors stands out. From the smaller setting to the clinically focused debates, it offers something different. Hear her perspective and see why you should join us on Sept 13-14.
Learn More: gdsolidtumors.com
#GDST #MedicalEducation #Cancer #Oncology
BTK or BCL-2? The evidence continues to evolve, and with it, treatment decisions in CLL. In this session at #GDHEM, Dr. Catherine Coombs reviews the latest data on sequencing strategies, real-world AE management, and the role of MRD and molecular profiling in guiding care.
www.gdhematology.com
GEJ cancer treatment planning isn’t always clear-cut.
At #GDST, Drs. Biachi and Uboha debate neoadjuvant vs adjuvant strategies—downstaging, recurrence risk, and the role of ctDNA in refining decisions.
Learn more: www.hmpglobalevents.com/gdst
#GEJcancer #Oncology #CancerResearch
Are ICIs more impactful in locally advanced cervical cancer—or in the first-line metastatic setting with chemo? At #GDST, Drs. Leath and Duska will debate timing, trial data, & patient-specific impact.
Join us in virtually or in Miami this September: gdsolidtumors.com
#CervicalCancer #WomensHealth
CTLA-4 inhibitors aren’t standard in NSCLC but could that change? At #GDST, Drs. Rodriguez and Raez debate the potential role of CTLA-4 inhibition in lung cancer treatment today.
Join us in Miami or virtually this September.
Learn more: gdsolidtumors.com
#LungCancer #NSCLC #Immunotherapy #Oncology
Still time to register for #GDHEM this month in NYC.
Leaders in leukemia, lymphoma & myeloma will debate today’s most pressing treatment questions—so you leave with strategies that translate to clinic.
📍 June 28–29 | InterContinental Times Square
🔗 gdhematology.com
#MedicalEducation #CancerCare
What’s next for low- and intermediate-risk MDS?
Dr. Aditi Shastri joins us in New York City this month to talk symptom control, PROMs, and tailoring care for real patients—not just protocols.
🔗 gdhematology.com
#MDS #Hematology #Oncology #CancerCare
@mskcancercenter.bsky.social
18.06.2025 14:11 — 👍 0 🔁 0 💬 0 📌 0
Frontline treatment in advanced HCC continues to evolve.
At #GDST, Drs. Harding and Alese will debate VEGF inhibition + ICI vs dual checkpoint blockade—exploring efficacy, sequencing, and patient selection.
Join us for this pressing debate: www.hmpglobalevents.com/gdst
#HCC #CancerCancer
@weillcornell.bsky.social
17.06.2025 14:00 — 👍 0 🔁 0 💬 0 📌 0
First-line treatment in #DLBCL is evolving—fast.
At #GDHEM, Dr. Sarah Rutherford reviews new frontline strategies, key trial data, and where care is headed for high-risk patients.
Join us this month in New York City. Learn more at gdhematology.com
#Lymphoma #Hematology #Oncology #ClinicalTrials
We’re heading to NYC this month for #GDHEM and proud to feature this outstanding group of faculty from across New York and New Jersey.
Wondering how your peers are tackling the toughest questions in hematology? Join the conversation.
🔗 gdhematology.com
#MedicalEducation #Oncology #Hematology
What if we treated by target, not tissue?
At #GDST, Dr. David Hong explores the future of tumor-agnostic therapies—molecular drivers, AI, and what it means for precision oncology.
Join us this September in Miami or virtually: www.hmpglobalevents.com/gdst
#TargetedTherapy #Oncology #CancerCare
Frontline myeloma care is changing fast.
At #GDHEM, Dr. @jmikhaelmd.bsky.social breaks down the shift to quadruplets, recent FDA approvals, and what’s next for transplant-eligible and ineligible patients.
Join us in NYC: gdhematology.com
#Myeloma #Hematology #Oncology @cityofhope.bsky.social
Earlier use of novel endocrine therapies in HR+ breast cancer: do they make a difference here?
Join Drs. Wander and Gandhi at #GDST as they debate the evidence, uncertainty, and impact of rethinking treatment lines.
📅 Sept 13–14
🔗 www.hmpglobalevents.com/gdst
#BreastCancer #Oncology #bcsm
On #NationalCancerSurvivorsDay, we recognize the strength, persistence, and presence of cancer survivors everywhere.
Your experiences continue to shape the future of care and support.
#CancerSurvivorship #Oncology
📣 Meet the Florida-based experts shaping this year’s #GDST!
Drs. Tiago Biachi, Gilberto Lopes, Nipun Merchant, Luis Raez, and @latinamd.bsky.social will join the debate-driven faculty lineup in Miami this September.
Learn more: hubs.ly/Q03qLVx30
#MedicalEducation #CancerCare #Oncology
📣 Meet the Co-Chairs for #GDHEM!
Drs. Jessica K. Altman, @johnpleonardmd.bsky.social, @jmikhaelmd.bsky.social are shaping a dynamic program that will tackle evolving standards and real-world decision-making in #hematology.
Learn more: gdhematology.com
#Oncology #Leukemia #Lymphoma #Myeloma
🩸 Every 27 seconds, someone in the world is diagnosed.
On #WorldBloodCancerDay, we recognize how quickly a life can change. Blood donors are critical in the treatment of #leukemia, #lymphoma, #myeloma, and other #bloodcancers. If you're able, consider #BloodDonation and being part of that change.
🧬 Should all high-risk smoldering myeloma patients be treated?
With new therapies available, is it time to move past “watch and wait”?
Join Peter Voorhees, MD & Faith Davies, MD for this timely #GDHEM debate.
🗓️ NYC: June 28–29 | LA: July 26–27
🔗 gdhematology.com
#Myeloma #Hematology #Oncology
Oncology Nursing Month | Oncology nurses are the steady hands behind every breakthrough.
Oncology nurses do more than care — they lead, advocate, and inspire.
This #OncologyNursingMonth, we recognize their power to care beyond limits.
#CaringBeyondLimits #OncologyNursing #CancerCare
Our Spring 2025 #DayofGiving is a week away! Register on May 21 for any Great Debates event & support the life-saving work of #LLS.
We proudly support Janelle Bradley's campaign in memory of her father: hubs.ly/Q03ml5SY0
Register on May 21:
#GDHEM: hubs.ly/Q03mk_qd0
#GDST: hubs.ly/Q03ml5Qf0
🚨 Is Chemotherapy Still Necessary for Ph+ ALL?
Join Elias Jabbour, MD and Shira Dinner, MD this summer as they debate "The Optimal Treatment Regimen for Ph+ ALL: Chemo-Free vs. Chemo + Allo-SCT."
Where do you stand? Comment below!
🔗 gdhematology.com
#GDHEM #Leukemia #BloodCancer
Today is #WorldOvarianCancerDay.
We stand with those raising awareness, pushing for better care, and supporting all affected by ovarian cancer.
#WOCD2025 #NoWomanLeftBehind #Oncology
